Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -5612.23% is 34% below its 3-year average of -4197.17%, near the low end of its 3-year range (-6902.69%–-1508.70%).
4.50% below its 12-month average of -5370.32%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5474.51%.
EBITDA MARGIN
-5612.23%
EBITDA MARGIN AVG TTM
-5370.32%
EBITDA MARGIN AVG 3Y
-4197.17%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.50%
CURRENT VS 3Y AVG
-33.71%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Upstream Bio, Inc.
Market Cap
$249.79M
EBITDA Margin
-5612.23%
TTM Avg
-5370.32%
3Y Avg
-4197.17%
5Y Avg
N/A
Market Cap
$248.50M
EBITDA Margin
-1441.45%
TTM Avg
-4661.83%
3Y Avg
-5918.79%
5Y Avg
-3944.51%
Market Cap
$247.27M
EBITDA Margin
-38.32%
TTM Avg
-70.22%
3Y Avg
-602.02%
5Y Avg
-454.95%
Market Cap
$255.88M
EBITDA Margin
-4.72%
TTM Avg
-1.10%
3Y Avg
6.56%
5Y Avg
4.38%
Market Cap
$256.47M
EBITDA Margin
-1857.26%
TTM Avg
-1020.57%
3Y Avg
-1032.24%
5Y Avg
-903.20%
Market Cap
$241.94M
EBITDA Margin
6.37%
TTM Avg
-0.39%
3Y Avg
-2.45%
5Y Avg
1.13%
Market Cap
$241.39M
EBITDA Margin
32.18%
TTM Avg
32.18%
3Y Avg
-276.01%
5Y Avg
-1681.16%
Market Cap
$241.34M
EBITDA Margin
-3813.88%
TTM Avg
-3607.01%
3Y Avg
-5701.50%
5Y Avg
-5701.50%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Upstream Bio, Inc. (UPB) | $249.79M | -5612.23% | -5370.32% | -4197.17% | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | -1441.45% | -4661.83% | -5918.79% | -3944.51% |
| Galectin Therapeutics Inc. (GALT)vs › | $247.62M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | -38.32% | -70.22% | -602.02% | -454.95% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | -4.72% | -1.10% | 6.56% | 4.38% |
| AC Immune S.A. (ACIU)vs › | $256.47M | -1857.26% | -1020.57% | -1032.24% | -903.20% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | 6.37% | -0.39% | -2.45% | 1.13% |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 32.18% | 32.18% | -276.01% | -1681.16% |
| Quantum-Si incorporated (QSI)vs › | $241.34M | -3813.88% | -3607.01% | -5701.50% | -5701.50% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -5226.40% | -5226.40% | -5226.40% | -21156.92% |
Gross Margin
98.5%
EBITDA Margin
-5612.2%
Operating Margin
-5618.8%
Net Margin
-4955.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -5474.51% |
| 2026-03-31 | -4213.35% |
| 2025-12-31 | -6902.69% |
| 2025-09-30 | -5532.65% |
| 2025-06-30 | -4728.39% |
| 2025-03-31 | -5648.41% |
| 2024-12-31 | -4285.32% |
| 2024-09-30 | -3110.21% |
| 2024-06-30 | -3436.67% |
| 2024-03-31 | -2343.75% |
| 2023-12-31 | -3181.33% |
| 2023-09-30 | -1508.70% |
